About Us

Corporate Sponsors

The Australian Nuclear Science and Technology Organisation (ANSTO) is the centre of Australia's nuclear science capabilities and expertise, operating the Open Pool Australian Lightwater (OPAL) reactor - the country's only nuclear reactor. 

ANSTO supplies a range of radiopharmaceutical products and accessories, services and training to the nuclear medicine industry working together to improve patient outcomes.  

Clarity utilises its strong imaging capability and proprietary technology to develop novel radiopharmaceuticals. Its in-house drug development program is focused on developing novel targeted therapeutics in oncology using a theranostic approach. Clarity's lead compound, SARTATE™, is entering Cu-64/Cu-67 theranostic trials in neuroendocrine tumours.  This new agent will also potentially allow better treatment of paediatric cancers and is entering clinical trials for neuroblastoma. Clarity is in a number of negotiations to expand its program and tap into new markets that can be better served with the SAR- Technology. As such, the prostate cancer market remains a key focus for the Company. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current technologies. Clarity is also in early preclinical development with a small range of other therapeutic oncology indications. In other serious diseases, Clarity is developing imaging-based companion diagnostics in areas including cardiovascular disease and fibrosis.

 

At Global Medical Solutions Australia (GMS), we utilise our extensive local and global business presence and expertise to deliver customer centric solutions in medical imaging practice. We strive to achieve outcomes above and beyond customer expectations through our flexible and collaborative approach. With a wealth of knowledge and experience in Nuclear Medicine and PET, you can be sure that we understand the nuances and complexities of your business.

Since 2003, Global Medical Solutions core business of centralised pharmacy has expanded and diversified to meet the increasing demands of our customers. Entrusted with this confidence, Global Medical Solutions has become Australia’s leading supplier of medical imaging products and services. By utilising our global partnerships, we can source the latest diagnostic and therapeutic tracers to ensure that your practice can provide the highest level of patient care.

Ipsen provides speciality medicines to healthcare professionals and their patients suffering from debilitating diseases.

At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare professionals. Ipsen is the Australian affiliate of a global research and development focused parent company.

Sirtex Medical Limited (Sirtex) is an Australian publicly listed company operating globally with offices in Australia, the US, Europe and Asia Pacific. The Sirtex primary objective is to research and develop effective treatments for liver cancer using novel small particle technology. The lead product of Sirtex, SIRSpheres Y-90 resin microspheres, is a form of targeted internal radiotherapy which enables high doses of absorbed radiation to treat extensive unresectable liver tumours whilst conserving normal liver parenchyma. Sirtex is supporting an extensive and ongoing programme of both prospective and randomised clinical studies with SIR-Spheres (c)  Y-90 resin microspheres in liver cancer including collaborative group and investigatorinitiated studies as well as those run directly by the company.